In this video interview, David Morton, PhD, director of biostatistics at Certara, explains how regulatory momentum is ...

A new index for the country’s most lucrative export has been lower than the long-time benchmark for the vast majority of days ...

Good afternoon, everyone, and welcome to the Caris Life Sciences Q4 2025 Earnings Call. My name is Dana, and I will be your coordinator today. Thank you. Earlier today, Caris Life Sciences released ...

Introduction Implementing shared decision-making (SDM) in maternity care remains challenging in low-income and middle-income ...

Introduction Burnout among healthcare professionals remains a critical public health issue linked to impaired cognition, emotional exhaustion and diminished clinical performance. Structured breathing ...

Introduction Intensive care unit (ICU) visiting restrictions in hospitals, implemented due to infection control and other factors, limited contact between patients and family members, affecting ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

MediWound (NASDAQ:MDWD) executives said 2025 marked a “pivotal year” for the company, highlighting progress in its late-stage ...

When Elise Felicione tried to design a clinical trial for a supplement, 5 things got in the way. It’s a lesson for the ...

Rhythm Pharmaceuticals Inc (RYTM) reports a 50% increase in full-year revenue and prepares for significant product launches amid ongoing financial challenges.

In paediatrics, “more trials have been done over the last ten years, but we have struggled with transparency and clarity, and sometimes with the quality because they are not always asking the ...

FDA Approval for Pediatric Indication -- LINZESS received U.S. FDA approval in November 2025 for IBS-C patients aged 7-17, ...